Project Grant R01HL176822

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $717,246.00 to The Leland Stanford Junior University to conduct research on the cardiovascular toxicity associated with proteasome inhibitor cancer treatments. The project aims to leverage mouse models, human induced pluripotent stem cells, CRISPR gene editing, and bioinformatics to elucidate the molecular mechanisms underlying proteasome inhibitor-induced cardiovascular dysfunction, with a focus on pathogenic alternative splicing events in smooth muscle and endothelial cells. The researchers will further evaluate the potential of antisense oligonucleotides to mitigate these cardiovascular side effects, with the goal of enabling safer administration of life-saving proteasome inhibitor-based cancer therapies. The award period runs from January 1, 2025 to December 31, 2028.